Pharmaceutical Preparations · DE · CIK 1400118
Developing novel FASN inhibitors for metabolic and fibrotic diseases like MASH, acne, and cancer
Comparable business profile · signals at a glance
In the 90 days to Feb 10, 2026: 5 sold $395K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Feb 10, 2026 | Happel DavidPresident & CEO | Sell | 12,101 | $5.36 | $65K |
| Feb 10, 2026 | Martins Eduardo BrunoChief Medical Officer | Sell | 3,640 | $5.36 | $20K |
| Feb 10, 2026 | Rozek ElizabethChief Legal & Admin. Officer | Sell | 2,622 | $5.36 | $14K |
| Feb 10, 2026 | Chauche ThierryChief Financial Officer | Sell | 1,312 | $5.36 | $7K |
| Nov 20, 2025 | Kemble GeorgeExecutive Chairman | Sell | 37,688 | $7.69 | $290K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.